Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the evidence for using oral medications to treat central serous chorioretinopathy, highlighting eplerenone as having the most support despite a lack of robust efficacy across studies.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This study found that serum irisin levels were significantly lower in patients with androgenetic alopecia compared to healthy controls, but no significant relationship was detected between serum irisin levels and insulin resistance markers like BMI, fasting insulin, or HOMA-IR.

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

This article highlights the potential for latanoprost acid, a metabolite of the glaucoma medication latanoprost, to serve as an effective alternative to current treatments for androgenetic alopecia, such as minoxidil and finasteride, facilitating a faster development process for related drugs.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study found that Japanese patients with alopecia areata had higher body mass index and retinol intake, with retinol intake being a predictor of hair loss severity.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

Spironolactone might help protect against severe lung problems in COVID-19 patients.

This study found that escalating baricitinib to 6 mg daily improved hair loss in 75% of patients with severe refractory alopecia areata who responded poorly to standard treatments, while also noting manageable short-term safety concerns under close monitoring.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

This study used molecular docking simulations to identify approved drugs, including Bedaquiline and Telmisartan, with potential to treat Onchocerca volvulus infections by inhibiting key protein targets, suggesting these drugs could be repurposed for onchocerciasis treatment with further validation.

This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.

This study found that manipulating AKR1D1 expression in human liver cells effectively regulates glucocorticoid clearance and receptor activation, highlighting its role in liver-specific steroid hormone regulation.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study found that the retinoid LGD1069 suppressed mammary tumorigenesis in a mouse model without observable toxicity, while TTNPB showed modest effects but was associated with significant toxicity.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Ritlecitinib works well and is safe for treating alopecia areata.

In this study, researchers used computational methods to identify six phytochemicals from nettle, saw palmetto, and fenugreek as effective binders to 5-alpha reductase, with Jamogenin showing enhanced stability when encapsulated in lipid nanoparticles.

This study demonstrated that methylation of the 5-alpha reductase type 2 (5-AR2) promoter is linked to reduced expression of the 5-AR2 protein, possibly explaining resistance to Finasteride in some BPH patients.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.

This review article concluded that certain herbal remedies targeting 5-alpha reductase inhibitors may prevent hair loss in androgenetic alopecia by blocking dihydrotestosterone production, although standardizing the concentration of active herbal compounds remains a challenge.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.